Ianalumab Safely Lowers Sjögren Activity at High Dose in Clinical
https://sjogrenssyndromenews.com/news/ianalumab-vay736-eases-sjogrens-symptoms-over-year-phase-2b-trial/
WEBNov 9, 2021 · Ianalumab (VAY736), an investigational antibody to treat Sjögren’s syndrome, at high dose was well-tolerated by patients using it for one year, and led to reductions in disease activity and significantly greater saliva production, data from a Phase 2b clinical trial show.
DA: 65 PA: 20 MOZ Rank: 91 Up or Down: Up